Drug Profile
Research programme: cancer stem cell vaccines - Pro-Cure/Adjuvantix
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Adjuvantix; Pro-Cure Therapeutics
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in United Kingdom (Parenteral)
- 21 May 2009 Preclinical trials in Prostate cancer in United Kingdom (Parenteral)